Table 4.
Table to present recent results of Contact X-Ray Brachytherapy (CXB) combined with external beam radiotherapy (EBRT) for rectal adenocarcinoma.
| Name, year | Recruitment period | Total no. of patients reported (no. receiving CXB alone) | EBRT dose | CXB dose | Response rates | Toxicity |
|---|---|---|---|---|---|---|
| Gérard, 2002 [49] | 1986–1998 | 63 | 39 Gy/13F | 35–140 Gy/1-4F (mean 80 Gy/3F) | cCR 58/63 (92%) LR-18/58 (31%) OS-64% 5 year, 45% 10 year |
0% G3/4 toxicity |
| Sun Myint, 2017 [47] | 2003–2012 | 200 (17) | 45/25F + chemo (127), 39 Gy/13F or 25 Gy/5F if unfit (56) | Mean 90/3F before or after | cCR 144/200 (72%)-plus 8 /38 had pathCR at surgery LR 16/144 (11%) DFS 53% 5 years |
0% G3/4 toxicity 39% G1/2 bleeding 30% G1 rectal ulcer |
| Dhadda, 2017 [41] | 2011–2015 | 45 (3) |
45 Gy/25F + capecitabine or 25 Gy/5F if unfit | 90/3F before or after | cCR 36/42 (86%) LR 5/36 (14%) 2 year |
1/42 (2%) G3 toxicity |
| Frin, 2017 [39] | 2002–2014 | 112 (20) |
50 Gy/25F ± chemo |
60–90/2-3F before or after | T2-early T3, N0 group 43/45 (96%) cCR LR 3/43 (11%) 5 yr |
9% (8/92) late G3 toxicity (including 3 fistulae post APER) 4/45 in T2-early T3,N0 group |
| Gérard, 2019 [50] | 2002–2016 | 74 (2) |
50 Gy/25F (69) + chemo (49/69) 25 Gy/5F (3) |
90–110 Gy/3-4F before or after | cCR 69/74 (93%) at 1 year (cCR 31/74 at 14 weeks) LR 7/71 (10%) 5 yr DFS 88% 3 yr OS 74% 3 yr |
11% (8/74) late G3 toxicity Rectal bleeding 34% late G1/2, 10% G3 |
ERUS Endo rectal ultrasound.
F fractions.
cCR clinical complete response.
LR local relapse.
OS overall survival.